Niagen Bioscience Inc
NAGE - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$198.31M
Close$
$-0.55
121.9% downside
Current Fair Value
121.9% downsideOvervalued by 121.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $198.31 Million |
|---|---|
| Enterprise Value | $134.22 Million |
| Earnings per Share | $0.22 |
| Beta | 2.02 |
| Outstanding Shares | 79,322,000 |
Return
| Return on Equity | 19.38% |
|---|---|
| Return on Assets | 15.00% |
| Return on Invested Capital | 11.98% |
Valuation & Multiples
| P/E Ratio | 13.85 |
|---|---|
| PEG | -18.89 |
| Price to Sales | - |
| Price to Book Ratio | 2.5 |
| Enterprise Value to Revenue | 4.51 |
| Enterprise Value to EBIT | 12.24 |
| Enterprise Value to Net Income | 8 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$0.01
Consensus analyst estimateRevenue Estimate
$30.53 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$-0.01
Consensus analyst estimateRevenue Estimate
$33.71 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Chromadex Corp
117 employees
CEO: Robert Fried
ChromaDex Corp. is a science-based integrated nutraceutical company devoted to improving the way people age. ChromaDex scientists partner with leading universities and research institutions worldwide to discover, develop and create solut...